Our data provide evidence that baseline plasma NT-proBNP level may be used as an easy, effective and safe marker to predict the immediate outcome of cardioversion with flecainide in patients with acute-onset < 24 h symptomatic AF. The gene discussed is NPPB; the disease is atrial fibrillation.